Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

a technology of pyridinyl and pyrimidinyl derivatives, which is applied in the direction of heterocyclic compound active ingredients, drug compositions, and metabolic disorders, can solve the problems of elevated blood glucose levels, serious health problems, and inability to move glucose into the cells of the individual, and achieve the effect of reducing the weight gain of the individual

Inactive Publication Date: 2006-07-13
ARENA PHARMA
View PDF0 Cites 73 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0042] Some embodiments of the present invention include a method of modulating a RUP3 receptor in an individual comprising contacting the...

Problems solved by technology

However, people who have diabetes either don't produce insulin or can't efficiently use the insulin they produce; therefore, they can't move glucose into their cells.
Glucose accumulates in the blood creating a condition called hyperglycemia, and over time, can cause serious health problems.
NIDDM is characterized by a relative disparity between endogenous insulin production and insulin requirements, leading to elevated blood glucose levels.
In addition, the onset can be insidious or even clinically inapparent, making diagnosis difficult.
However, after several decades, β cell function deteriorates and non-insulin-dependent diabetes develops in about 20% of the obese population (Pederson, P.
However, the factors which predispose a fraction of patients to alteration of insulin secretion in response to fat accumulation remain unknown.
There are problems with this definition in that it does not take into account the proportion of body mass that is muscle in relation to fat (adipose t...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
  • Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
  • Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

Examples

Experimental program
Comparison scheme
Effect test

example 1

96-well Cyclic AMP Membrane Assay for RUP3

Materials:

[0358] 1) Adenlyl cyclase Activation Flashplate Assay kit from Perkin Elmer—96 wells (SMP004B) and 125I tracer (NEX130) which comes with the kit. Keep in refrigerator, in a box, and do not expose the Flashplates to light. [0359] 2) Phosphocreatine—Sigma P-7936 [0360] 3) Creatine Phosphokinase—Sigma C-3755 [0361] 4) GTP—Sigma G-8877 [0362] 5) ATP—Sigma A-2383 [0363] 6) IBMX—Sigma 1-7018 [0364] 7) Hepes—1M solution in distilled water—Gibco #15630080 [0365] 8) MgCl2—Sigma M-1028—1M Solution [0366] 9) NaCl—Sigma —S6546—5M Solution [0367] 10) Bradford Protein Assay Kit—Biorad # 5000001 [0368] 11) Proclin 300—Sigma #4-8126

Binding Buffer—filter through 45-micron Nalgene filter and keep in refrigerator. All buffers and membranes should be kept cold (in ice bucket) while performing assay.

20 mM Hepes, pH 7.4

1 mM MgCl2

100 mM NaCl

2× Regeneration Buffer (make in binding buffer):

20 mM Phosphocreatine (1.02 gm / 200 ml binding buf...

example 2

A. RT-PCR Analysis of RUP3 Expression in Human Tissues (FIG. 1A).

[0409] RT-PCR was applied to determine the tissue distribution of RUP3. Oligonucleotides used for PCR had the following sequences:

ZC47:(SEQ ID NO:3)5′-CATTGCCGGGCTGTGGTTAGTGTC-3′ (forward primer),;ZC48:(SEQ ID NO:4)5′-GGCATAGATGAGTGGGTTGAGCAG-3′ (reverse primer),;

[0410] and the human multiple tissue cDNA panels (MTC, Clontech) were used as templates (1 ng cDNA per PCR amplification). Twenty-two (22) human tissues were analyzed. PCR was performed using Platinum PCR SuperMix (Life Technologies, Inc.; manufacture instructions were followed) in a 50 μl reaction by the following sequences: step 1, 95° C. for 4 min; step 2, 95° C. for 1 min; step 3, 60° C. for 30 sec; step 4, 72° C. for 1 min; and step 5, 72° C. for 7 min. Steps 2 through 4 were repeated 35 times.

[0411] The resulting PCR reactions (15 □l) were loaded on a 1.5% agarose gel to analyze the RT-PCR products, and a specific 466 base-pair DNA fragment represen...

example 3

RUP3 Protein Expression is Restricted to β Cell Lineage of Pancreatic Islets (FIG. 2).

[0418] A. A Polyclonal Anti-RUP3 Antibody was Prepared in Rabbits (FIG. 2A).

[0419] Rabbits were immunized with an antigenic peptide with sequence derived from rat RUP3 (“rRUP3”). The peptide sequence was RGPERTRESAYHIVTISHPELDG (SEQ ID NO: 7) and shared 100% identity with mouse RUP3 in the corresponding region. A cysteine residue was incorporated at the N-terminal end of this antigenic peptide to facilitate KLH crosslinking before injecting into rabbits. The resulting antisera (“anti-rRUP3”) and the corresponding preimmune sera (“pre-rRUP3”) were tested for immune reactivity to mouse RUP3 in immunobloting assays (lanes 1 though 4). In this assay, the GST-RUP3 fusion protein was readily recognized by the anti-rRUP3 antisera (lane 4), but not by the preimmune sera (lane 2). The immunoreactive signal could be efficiently eliminated when the immunobloting assay was performed in the presence of exces...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Login to view more

Abstract

The present invention relates to certain substituted pyridinyl and pyrimidinyl derivatives of Fomula (Ia) that are modulators of metabolism.
Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Ser. No. 60 / 642,840, filed Jan. 10, 2005, the disclosure of which is incorporated herein by reference in its entirety.FIELD OF THE INVENTION [0002] The present invention relates to certain substituted pyridinyl and pyrimidinyl derivatives that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity. BACKGROUND OF THE INVENTION [0003] Diabetes mellitus is a serious disease afflicting over 100 million people worldwide. In the United States, there are more than 12 million diabetics, with 600,000 new cases diagnosed each year. [0004] Diabetes mellitus is a diagnostic term for a group of disorders characterized by abnormal glucose homeostasis resulting in elevated blood sugar. There are many types of diabetes, but the two most common are Type I (also refe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/513C07D403/14C07D401/14
CPCC07D401/12C07D401/14C07D405/14C07D413/14A61P3/00A61P3/04A61P3/06A61P43/00A61P3/10A61K31/505A61K31/44
Inventor JONES, ROBERTLEHMANN, JUERGWONG, AMYHURST, DAVIDSHIN, YOUNG-JUN
Owner ARENA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products